Claritev Q1 revenue $231.3M (-1.4% YoY); net loss $71.3M vs $539.7M; reaffirms FY guidance

Claritev Corp

2025-Q1 EPS reported -$4.38 revenue$231,330,000

Revenue $231.3M, down 1.4% from $234.5M; net loss improved to $71.3M from $539.7M.
Adjusted EBITDA $142.1M (61.4% margin) vs $146.8M in prior year.
Free cash flow negative $(68.9)M vs positive $19.2M; cash $23.1M.
Reaffirmed FY2025 guidance: revenue (2)% to flat, Adj. EBITDA margin 62.5%-63.5%, FCF $(65)-$(75)M.
Announced strategic alliances with Oracle, J2 Health, and Burjeel Holdings; new Chief Medical and AI officers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.